Related references
Note: Only part of the references are listed.Diffusion and Perfusion MRI to Differentiate Treatment-Related Changes Including Pseudoprogression from Recurrent Tumors in High-Grade Gliomas with Histopathologic Evidence
A. J. Prager et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2015)
Dynamic susceptibility contrast MRI measures of relative cerebral blood volume as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 multicenter trial
Kathleen M. Schmainda et al.
NEURO-ONCOLOGY (2015)
Relative cerebral blood volume is a potential predictive imaging biomarker of bevacizumab efficacy in recurrent glioblastoma
Philipp Kickingereder et al.
NEURO-ONCOLOGY (2015)
Precise ex vivo histological validation of heightened cellularity and diffusion-restricted necrosis in regions of dark apparent diffusion coefficient in 7 cases of high-grade glioma
Peter S. LaViolette et al.
NEURO-ONCOLOGY (2014)
Sustained focal antitumor activity of bevacizumab in recurrent glioblastoma
Oliver Baehr et al.
NEUROLOGY (2014)
Bevacizumab for Newly Diagnosed Glioblastoma Reply
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Glioma: Application of Whole-Tumor Texture Analysis of Diffusion-Weighted Imaging for the Evaluation of Tumor Heterogeneity
Young Jin Ryu et al.
PLOS ONE (2014)
Bevacizumab plus Radiotherapy-Temozolomide for Newly Diagnosed Glioblastoma
Olivier L. Chinot et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Restriction-spectrum aging of bevacizumab-related necrosis in a patient with GBM
Nikdokht Farid et al.
FRONTIERS IN ONCOLOGY (2013)
Persistent Diffusion-Restricted Lesions in Bevacizumab-Treated Malignant Gliomas Are Associated with Improved Survival Compared with Matched Controls
S. Mong et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2012)
Volumetric and MGMT parameters in glioblastoma patients: Survival analysis
Georgios Iliadis et al.
BMC CANCER (2012)
Prostate Cancer Aggressiveness: In Vivo Assessment of MR Spectroscopy and Diffusion-weighted Imaging at 3 T
Thiele Kobus et al.
RADIOLOGY (2012)
Isolated Diffusion Restriction Precedes the Development of Enhancing Tumor in a Subset of Patients with Glioblastoma
A. Gupta et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
Apparent Diffusion Coefficient Histogram Analysis Stratifies Progression-Free Survival in Newly Diagnosed Bevacizumab-Treated Glioblastoma
W. B. Pope et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2011)
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
Albert Lai et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Patterns of progression in patients with recurrent glioblastoma treated with bevacizumab
W. B. Pope et al.
NEUROLOGY (2011)
Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastoma
Olivier Keunen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Bevacizumab for the Treatment of Recurrent Glioblastoma
Marc C. Chamberlain
CLINICAL MEDICINE INSIGHTS-ONCOLOGY (2011)
Diffusion-Weighted MR Imaging Derived Apparent Diffusion Coefficient Is Predictive of Clinical Outcome in Primary Central Nervous System Lymphoma
R. F. Barajas et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2010)
Diffusion Magnetic Resonance Imaging Detects Pathologically Confirmed, Nonenhancing Tumor Progression in a Patient With Recurrent Glioblastoma Receiving Bevacizumab
Elizabeth R. Gerstner et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Updated Response Assessment Criteria for High-Grade Gliomas: Response Assessment in Neuro-Oncology Working Group
Patrick Y. Wen et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Imaging response criteria for recurrent gliomas treated with bevacizumab: Role of diffusion weighted imaging as an imaging biomarker
Rajan Jain et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
The imaging and neuropathological effects of Bevacizumab (Avastin) in patients with leptomeningeal carcinomatosis
B. K. Kleinschmidt-DeMasters et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging
James P. B. O'Connor et al.
CLINICAL CANCER RESEARCH (2009)
Pseudoprogression and pseudoresponse in the treatment of gliomas
Dieta Brandsma et al.
CURRENT OPINION IN NEUROLOGY (2009)
Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma
Henry S. Friedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Single-Agent Bevacizumab Followed by Bevacizumab Plus Irinotecan at Tumor Progression in Recurrent Glioblastoma
Teri N. Kreisl et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Patterns of relapse and prognosis after bevacizumab failure in recurrent glioblastoma
F. M. Iwamoto et al.
NEUROLOGY (2009)
Recurrent Glioblastoma Multiforme: ADC Histogram Analysis Predicts Response to Bevacizumab Treatment
Whitney B. Pope et al.
RADIOLOGY (2009)
Immortal time bias in pharmacoepidemiology
Samy Suissa
AMERICAN JOURNAL OF EPIDEMIOLOGY (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma
Marc C. Chamberlain
JOURNAL OF CLINICAL ONCOLOGY (2008)
Bevacizumab plus irinotecan in recurrent glioblastoma multiforme
James J. Vredenburgh et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging
Qing-Shi Zeng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Immortal time bias in observational studies of drug effects
Samy Suissa
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2007)
Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma
James J. Vredenburgh et al.
CLINICAL CANCER RESEARCH (2007)
Apparent diffusion coefficient histograms may predict low-grade glioma subtype
Daniel J. Tozer et al.
NMR IN BIOMEDICINE (2007)
Hypoxia-inducible factor 1 and VEGF upregulate CXCR4 in glioblastoma: implications for angiogenesis and glioma cell invasion
David Zagzag et al.
LABORATORY INVESTIGATION (2006)
Malignant astrocytic tumors: Clinical importance of apparent diffusion coefficient in prediction of grade and prognosis
Shuichi Higano et al.
RADIOLOGY (2006)
Diffusion imaging: Insight to cell status and cytoarchitecture
Thomas L. Chenevert et al.
NEUROIMAGING CLINICS OF NORTH AMERICA (2006)
Vaso-occlusive and prothrombotic mechanisms associated with tumor hypoxia, necrosis, and accelerated growth in glioblastoma
DJ Brat et al.
LABORATORY INVESTIGATION (2004)
Pretreatment prediction of brain tumors' response to radiation therapy using high b-value diffusion-weighted MRI
Y Mardor et al.
NEOPLASIA (2004)
Vascular permeability factor/vascular endothelial growth factor: A critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy
HF Dvorak
JOURNAL OF CLINICAL ONCOLOGY (2002)
Monoclonal antibodies to vascular endothelial growth factor (VEGF) and the VEGF receptor, FLT-1, inhibit the growth of C6 glioma in a mouse xenograft
DF Stefanik et al.
JOURNAL OF NEURO-ONCOLOGY (2001)
Share Paper
